# Comment on “Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab”

**Authors:** Binghua Li, Qiang Wang, Weiwei Hu, Huan Li, Peng Yan, Yajuan Cao, Decai Yu

PMC · DOI: 10.1016/j.iliver.2024.100130 · ILIVER · 2024-11-07

## Full-text entities

- **Diseases:** hepatocellular carcinoma (MESH:D006528)
- **Chemicals:** atezolizumab (MESH:C000594389), bevacizumab (MESH:D000068258)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12212663/full.md

## References

10 references — full list in the complete paper: https://tomesphere.com/paper/PMC12212663/full.md

---
Source: https://tomesphere.com/paper/PMC12212663